Johnson & Johnson Vs. Pfizer: Consistency Vs. Volatil…

AccessibilityHelp

▲ S&P 500 +—%|▲ Stock Advisor +—%Join The Motley Fool

Arrow down

S&P 500

7,352.56

-0.9%

-64.03

Arrow down

DJI

50,961.66

-1.3%

-646.51

Arrow down

NASDAQ

24,326.02

-0.7%

-183.74

Arrow down

Bitcoin

$63,695.00

-1.9%

-$1,255.70

Arrow up

SPCX

$141.38

+2.9%

+$4.02

Arrow down

AAPL

$351.33

-0.4%

-$1.45

Arrow down

AMZN

$257.22

-0.2%

-$0.53

Arrow down

GOOG

$279.03

-0.8%

-$2.23

Arrow down

META

$622.75

-0.6%

-$3.66

Arrow down

MSFT

$503.76

-2.7%

-$14.23

Arrow down

NVDA

$153.99

-1.4%

-$2.15

Arrow up

TSLA

$380.47

+0.2%

+$0.73

Free ArticleExplore Premium Services

By Brendan Coffey – Nov 17, 2026 at 1:30PM EST

+Fool.comon

Key Points

  • Johnson & Johnson currently exhibits a stronger overall revenue profile than Pfizer by maintaining consistently higher absolute sales volume across every reported period.

  • Over roughly the last eight quarters, Johnson & Johnson achieved steady quarter-over-quarter revenue growth, while Pfizer experienced a volatile quarter-over-quarter trajectory marked by repeating fluctuations.

  • Investors should closely monitor whether the revenue gap between the two companies continues to widen in upcoming quarters or eventually begins to narrow.

NYSE · As of 1:31 PM ET 11/17/26

Premium Feature

Moneyball Superscore83/100

Key data points

Market capMarket cap calculated using publicly traded s outstanding only. Does not include unlisted, private, or dual-class non-traded s. Implied market cap may vary.$680.19B

Day’s range$277.56 – $281.72

52wk range$198.53 – $290.25

Volume2.5M

Avg volume7.1M

Gross margin67.65%

Dividend yield1.87%

Pfizer: Uneven and Volatile Recent Revenue Patterns

Pfizer (PFE -1.23%) primarily generates revenue by developing, manufacturing, and commercializing prescription medicines and vaccines for individuals worldwide.

It recently announced a $1.5 billion funding agreement with Blackstone Life Sciences, and it secured expanded regulatory approval from the U.S. Food and Drug Administration for a cancer treatment regimen.

PFE – Pfizer

$28.51-$0.36 (-1.23%)

NYSE · As of 1:30 PM ET 11/17/26

Premium Feature

Moneyball Superscore67/100

Key data points

Market capMarket cap calculated using publicly traded s outstanding only. Does not include unlisted, private, or dual-class non-traded s. Implied market cap may vary.$164.50B

Day’s range$28.43 – $28.67

52wk range$23.62 – $31.44

Volume13.5M

Avg volume33.7M

Gross margin65.10%

Dividend yield5.96%

Why Revenue Matters for Investors

Revenue here refers to the data provider’s standardized income-statement revenue line item, and it shows the total money a business brings in from sales before deducting any operating costs.

Johnson & Johnson vs. Pfizer Revenue chart

Johnson & Johnson vs. Pfizer Revenue over the last 8 quarters.

Quarterly Revenue for Johnson & Johnson and Pfizer

Calendar quarter Johnson & Johnson Revenue Pfizer Revenue
Q4 2024 $22.5 billion (quarter ended Dec. 29, 2024) $17.8 billion (quarter ended Dec. 31, 2024)
Q1 2025 $21.9 billion (quarter ended March 30, 2025) $13.7 billion (quarter ended March 30, 2025)
Q2 2025 $23.7 billion (quarter ended June 29, 2025) $14.7 billion (quarter ended June 29, 2025)
Q3 2025 $24.0 billion (quarter ended Sept. 28, 2025) $16.7 billion (quarter ended Sept. 28, 2025)
Q4 2025 $24.6 billion (quarter ended Dec. 28, 2025) $17.6 billion (quarter ended Dec. 31, 2025)
Q1 2026 $24.1 billion (quarter ended March 29, 2026) $14.4 billion (quarter ended March 29, 2026)
Q2 2026 $25.3 billion (quarter ended June 28, 2026) $15.0 billion (quarter ended June 28, 2026)
Q3 2026 $25.4 billion (quarter ended Sept. 27, 2026) $16.6 billion (quarter ended Sept. 27, 2026)

Foolish Take

First off, don’t be concerned about the drops in revenue you see in the chart for both companies as you read left to right. That reflects the seasonality of the businesses, which often can be traced back to doctors and patients loading up on prescriptions toward the end of a calendar year, when many patients have met their health insurance deductibles.

While ideally, a quarterly revenue chart would show rising bars from left to right, this seasonality means a better evaluation would be to compare each quarter to its prior-year quarter. For instance, JNJ’s third quarter of 2026 saw positive gains over the third quarter of 2025. Yet Pfizer’s sales actually show a slight dip in Q3 2026 compared to the same period in 2025. That’s a red flag for investors to pay attention to.

We also do see less fluctuation from JNJ, in part because the business has 28 products and platforms that each generate more than $1 billion in annual sales. Pfizer, meanwhile, is trying to recover from a post-COVID-19 letdown, with fewer people getting the COVID vaccine each year as we get further from the pandemic.

Data source: Financial Modeling Prep. Data as of Nov. 17, 2026.

Where to invest $1,000 right now

When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 802%* — a market-crushing outperformance compared to 205% for the S&P 500.

They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.

See the stocks ›

*Stock Advisor returns as of November 17, 2026.

Read Next

jnj-nvo_quarter_revenue_bar_primary_standard_limit8.png

•By Brendan Coffey

Johnson & Johnson vs. Novo Nordisk: Steady Uptrend vs. Flat Revenue

Johnson and Johnson logo -- source Johnson and Johnson JNJ

•By Matt DiLallo

How to Buy Johnson & Johnson Stock (JNJ) in 2026

26_10_08 A wooden percent sign next to a hand holding money _MF Dload GettyImages-1642477285-1281x720-273823a

•By Reuben Gregg Brewer

5 Dividend Stocks to Buy and Hold Forever

People near a healthcare facility.

•By Lyle Daly

How to Invest in Vanguard Health Care ETF (VHT)

Johnson_And_Johnson_Employee_Writing_on_glass_with_logo_jnj.jpg

•By Brendan Coffey

Johnson & Johnson vs. Eli Lilly: Which Healthcare Giant’s Stock Is a Better Buy for 2027?

Johnson & Johnson logo source-TMF

•By Prosper Junior Bakiny

Johnson & Johnson Sees a Path to Double-Digit Growth by 2030. Is the Dividend King a Buy?

About the Author

Brendan Coffey

Brendan Coffey is a contributing analyst at The Motley Fool. Brendan has been chief editor and analyst of stock investing newsletters and a member of Forbes Magazine’s market-beating stock picking team. He has also contributed to Bloomberg, Fortune.com, The Wall Street Journal and many other publications.

CMFbpcoffey

X@bpcoffey

Stocks Mentioned

Johnson & Johnson Stock Quote

Johnson & Johnson

NYSE: JNJ

$279.78

(-0.98%)-$2.77

Stock Advisor

Motley Fool Stock Advisor’s Latest Pick

Get Access

—% Avg Return

Pfizer Stock Quote

Pfizer

NYSE: PFE

$28.51

(-1.23%)-$0.36

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services.

View Premium Services

Sumber Artikel:

Fool.com

Baca Artikel Lengkap di Sumber

Patinko

Leave a Reply

Your email address will not be published. Required fields are marked *